Carboxyamidotriazole - ForwardVue Pharma
Alternative Names: CAI - ForwardVue Pharma; L-651582; MLS003373924; NSC609974Latest Information Update: 29 Jul 2021
At a glance
- Originator ForwardVue Pharma
- Class Eye disorder therapies; Heterocyclic compounds; Small molecules; Triazoles
- Mechanism of Action Angiogenesis inhibitors; ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 27 Jul 2021 Preclinical trials in Retinal disorders in USA (Intravitreous, Injection) prior to July 2021
- 27 Jul 2021 ForwardVue Pharma plans phase II trial for Retinal disorders in USA
- 24 Jun 2021 ForwardVue Pharma has worldwide patent protection for the methods of preparation of carboxyamidotriazole and its use in the treatment of inflammatory optic neuropathies